• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Curis Inc. (Amendment)

    2/14/22 4:42:48 PM ET
    $CRIS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $CRIS alert in real time by email
    SC 13G/A 1 c020822a.htm SCHEDULE 13G (AMENDMENT NO. 1)
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    (Name of Issuer)
    Curis, Inc.
    (Title of Class of Securities)
    Common Stock, Par Value $0.01 Per Share

    (CUSIP Number)

    231269200

    (Date of Event Which Requires Filing of this Statement)

    December 31, 2021

    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).



    CUSIP No. 231269200
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,442,543 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,442,543 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,442,543 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 1.6% (see Item 4)
     
    (12) Type of reporting person (see instructions) PN
     


    CUSIP No. 231269200
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,442,543 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,442,543 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,442,543 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 1.6% (see Item 4)
     
    (12) Type of reporting person (see instructions) CO
     


    CUSIP No. 231269200
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              143,487 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       143,487 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    143,487 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0.2% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 231269200
    (1) Names of reporting persons    Point72 Hong Kong Limited
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Hong Kong
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              17,133 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       17,133 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    17,133 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) OO
     


    CUSIP No. 231269200
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              1,603,163 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       1,603,163 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    1,603,163 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 1.8% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     


    Item 1(a) Name of issuer:
    Curis, Inc.
    Item 1(b) Address of issuer's principal executive offices:
    128 Spring Street, Building C – Suite 500, Lexington, MA 02421
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.01 per share
    (“Shares”), of the Issuer held by certain investment funds it manages; (ii)
    Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect
    to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; (iv) Point72 Hong Kong Limited (“Point72 Hong Kong”) with respect to
    Shares held by certain investment funds it manages; and (v) Steven A. Cohen
    (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Hong Kong.

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Hong Kong, and Mr. Cohen have entered into a Joint Filing
    Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1,
    pursuant to which they have agreed to file this Schedule 13G jointly in
    accordance with the provisions of Rule 13d-1(k) of the Act.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; (ii) Cubist Systematic Strategies is 55 Hudson Yards,
    New York, NY 10001; and (iii) Point72 Hong Kong is 12th Floor, Chater House, 8
    Connaught Road Central, Hong Kong.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital
    Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware
    limited liability company. Point72 Hong Kong is a Hong Kong limited liability
    company. Mr. Cohen is a United States citizen.
    2(d) Title of class of securities:

    Common Stock, Par Value $0.01 Per Share

    2(e) CUSIP Number:

    231269200

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on December 31, 2021:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 1,442,543
    (b) Percent of class: 1.6% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,442,543 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,442,543

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 1,442,543
    (b) Percent of class: 1.6% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,442,543 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,442,543

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 143,487
    (b) Percent of class: 0.2% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 143,487 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 143,487

    4. Point72 Hong Kong Limited
    (a) Amount beneficially owned: 17,133
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 17,133 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 17,133

    5. Steven A. Cohen
    (a) Amount beneficially owned: 1,603,163
    (b) Percent of class: 1.8% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 1,603,163 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 1,603,163

    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Hong Kong, and Mr. Cohen own directly no Shares. Pursuant
    to an investment management agreement, Point72 Asset Management maintains
    investment and voting power with respect to the securities held by certain
    investment funds it manages. Point72 Capital Advisors Inc. is the general
    partner of Point72 Asset Management. Pursuant to an investment management
    agreement, Cubist Systematic Strategies maintains investment and voting power
    with respect to the securities held by certain investment funds it manages.
    Pursuant to an investment management agreement, Point72 Hong Kong maintains
    investment and voting power with respect to the securities held by certain
    investment funds it manages. Mr. Cohen controls each of Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Hong Kong. As of December 31, 2021, by reason of the provisions of
    Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of (i) Point72
    Asset Management, Point72 Capital Advisors Inc. and Mr. Cohen may be deemed
    to beneficially own 1,442,543 Shares (constituting approximately 1.6% of the
    Shares outstanding), (ii) Cubist Systematic Strategies and Mr. Cohen may be
    deemed to beneficially own 143,487 Shares (constituting approximately 0.2% of
    the Shares outstanding) and (iii) Point72 Hong Kong and Mr. Cohen may be
    deemed to beneficially own 17,133 Shares (constituting <0.1% of the Shares
    outstanding). Each of Point72 Asset Management, Point72 Capital Advisors
    Inc., Cubist Systematic Strategies, Point72 Hong Kong, and Mr. Cohen disclaims
    beneficial ownership of any of the securities covered by this statement.
    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the
    securities referred to above were not acquired and are not held for the purpose
    of or with the effect of changing or influencing the control of the issuer of the
    securities and were not acquired and are not held in connection with or as a
    participant in any transaction having that purpose or effect, other than activities
    solely in connection with a nomination under§ 240.14a-11.


    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: February 14, 2022

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    POINT72 HONG KONG LIMITED
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    Get the next $CRIS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRIS

    DatePrice TargetRatingAnalyst
    5/19/2025$17.00Buy
    H.C. Wainwright
    11/17/2023$26.00Buy
    Truist
    4/4/2022Outperform → Mkt Perform
    Raymond James
    10/13/2021$15.00Outperform
    Raymond James
    More analyst ratings

    $CRIS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Board of Directors of Curis approved the grant of inducement stock options to its newly appointed Chief Medical Officer, Dr. Ahmed Hamdy to purchase 200,000 shares of Curis common stock, with a grant date of May 1, 2025 (the "Inducement Grant"). The Inducement Grant has an exercise price per share equal to the closing price of the Company's common stock

      5/6/25 6:16:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Provides First Quarter 2025 Business Update

      Curis strengthens executive team with the appointment of industry veteran Dr. Ahmed Hamdy as Chief Medical Officer Management to host conference call today at 8:30 a.m. ET LEXINGTON, Mass., May 6, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today reported its business update and financial results for the first quarter ended March 31, 2025. "I am pleased to announce the expansion of the Curis Executive Team with the addition of Dr. Ahmed Hamdy as

      5/6/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

      LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

      4/29/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    SEC Filings

    See more
    • SEC Form 10-Q filed by Curis Inc.

      10-Q - CURIS INC (0001108205) (Filer)

      5/6/25 8:04:49 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - CURIS INC (0001108205) (Filer)

      5/6/25 8:03:06 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Curis Inc.

      DEFA14A - CURIS INC (0001108205) (Filer)

      4/10/25 4:27:59 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by CMO Hamdy Ahmed Md

      4 - CURIS INC (0001108205) (Issuer)

      5/5/25 4:26:25 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3 filed by new insider Hamdy Ahmed Md

      3 - CURIS INC (0001108205) (Issuer)

      5/5/25 4:24:56 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO Duvall Diantha

      4 - CURIS INC (0001108205) (Issuer)

      1/30/25 4:11:25 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Leadership Updates

    Live Leadership Updates

    See more
    • Curis Adds Three New Executives to Management Team Strengthening Medical Affairs, Clinical Development and Clinical Operations

      LEXINGTON, Mass., Jan. 3, 2022 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of three new executives to its management team. Joining the company, are Felix Geissler, M.D., Ph.D., as Vice President of Medical Affairs, Kimberly Steinmann, M.D., as Vice President of Clinical Development, and Dora Ferrari, as Vice President of Clinical Operations. They will be reporting directly to Dr. Reinhard von Roemeling, Senior Vice President, Clinical Devel

      1/3/22 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Appoints John A. Hohneker, M.D. To Board Of Directors

      LEXINGTON, Mass., Dec. 6, 2021  /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced the appointment of John A. Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings 30 years of drug development and leadership experience within the biotech and pharmaceutical industries.  He most recently served as President and CEO of Anokion SA. Prior to Anokion, he was President of Research and Development at FORMA Therapeutics Inc., where he guided the company's transitio

      12/6/21 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

      LEXINGTON, Mass., Jan. 8, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that on January 4, 2021, the independent Compensation Committee of the Board of Directors of Curis approved the grant of inducement stock options to purchase a total of 185,000 shares of Curis common stock to three new employees, with a grant date of January 4, 2021 (the "Q1 2021 Inducement Grants"). Each of the Q1 2021 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on January 4, 2021. Each stock option has a 10 year term and vests ov

      1/8/21 4:01:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Curis Inc.

      SC 13G/A - CURIS INC (0001108205) (Subject)

      11/13/24 2:05:06 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Curis Inc.

      SC 13G - CURIS INC (0001108205) (Subject)

      11/1/24 4:35:37 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Curis Inc.

      SC 13G - CURIS INC (0001108205) (Subject)

      4/15/24 2:12:19 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Financials

    Live finance-specific insights

    See more
    • Curis to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2025

      LEXINGTON, Mass., April 29, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its first quarter 2025 financial and operating results on Tuesday, May 6, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast can

      4/29/25 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on March 31, 2025

      LEXINGTON, Mass., March 28, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its fourth quarter 2024 financial and operating results on Monday, March 31, 2025, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast c

      3/28/25 4:07:00 PM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis to Report Third Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on November 14, 2024

      LEXINGTON, Mass., Nov. 7, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will report its third quarter 2024 financial and operating results on Thursday, November 14, 2024, at 8:00 a.m. ET. Management will host a conference call and simultaneous webcast on the same day at 8:30 a.m. ET. Participants may join by dialing (800)-836-8184 from the United States or (646)-357-8785 from other locations or a live audio webcast

      11/7/24 8:00:00 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $CRIS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Curis with a new price target

      H.C. Wainwright resumed coverage of Curis with a rating of Buy and set a new price target of $17.00

      5/19/25 8:52:11 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Truist initiated coverage on Curis with a new price target

      Truist initiated coverage of Curis with a rating of Buy and set a new price target of $26.00

      11/17/23 7:37:50 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Curis downgraded by Raymond James

      Raymond James downgraded Curis from Outperform to Mkt Perform

      4/4/22 11:27:43 AM ET
      $CRIS
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care